A 53-year-old woman presents with a 3-year history of primary hypothyroidism. She has been receiving a stable dose of levothyroxine (LT4) replacement monotherapy and has had thyroid-stimulating hormone (TSH) levels of 0.5-2.5 mIU/L, well within the guideline-recommended range (0.45-4.12 Hypothyroidism is a relatively common condition. In the US National Health and Nutrition Examination Survey (NHANES) III, a prevalence of 4.6% was noted in participants ≥ 12 years of age.
Europe estimated a prevalence of 3.05%. 3 The frequency of elevated TSH increases with age, and in those aged 40 to 69 years, the prevalence of elevated TSH is significantly higher in women than in men.
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As TSH levels physiologically rise with aging, T3 levels decline to the same extent in those without thyroid disease, whereas T4 levels remain largely unchanged in the healthy elderly. 4 In patients with primary hypothyroidism, the thyroid gland is unable to maintain adequate secretion of hormones, triggering the pituitary gland to release greater amounts of TSH to compensate. 5 However, owing to dysfunction of the thyroid gland, endogenous production of thyroid hormones remains insufficient. Clinical manifestations of this insufficiency can vary greatly because thyroid hormone receptors are present in most organs and tissues of the body. 5 The cardiovascular, pulmonary, gastrointestinal, musculoskeletal and neurological systems can all be affected as well as the kidneys, skin and connective tissues.
The severity of the signs and symptoms of hypothyroidism can range from subclinical to debilitating. In the United States, where iodine deficiency is rare, the most common cause of hypothyroidism is autoimmune thyroiditis. Although thyroxine (T4) is considered a prohormone to the active form (ie, T3), T4 has a longer half-life 6 and is converted to T3 intracellularly, whereas T3 interacts with thyroid hormone receptor to affect thyroid-
hormone-responsive genes. Is there good clinical evidence to support the superiority of LT4/LT3 combination therapy for the treatment of patients with troublesome symptoms despite normal TSH levels? Is there benefit
in adding LT3 to an LT4 monotherapy regimen? Here, we review the evidence and rationale that underpin current approaches to treatment and explore potential solutions to the problem of persistent symptoms in a patient who has achieved a normal TSH level with LT4 replacement therapy.
| Literature search methods
Because older research has been well summarised, 7 recent literature indexed on PubMed was searched in March 2017 using the terms "hypothyroid" or "hypothyroidism" and "triiodothyronine combination" or "T3 combination." After limiting the results to the past 10 years and to non-review articles published in English, 72 articles were found; of these, 17 were relevant based on their analysis and discussion of thyroid replacement therapies, specifically LT4/LT3 combination therapy, in patients with hypothyroidism and are included here.
| Historical development of treatment for hypothyroidism
Initially, thyroid replacement therapies were desiccated thyroid extract preparations of animal origin, which contained variable amounts of T4 and T3. 8, 9 Development of synthetic formulations of both hormones enabled the administration of preparations with exact quantities of hormones; their testing as replacement therapy began in the 1950s. 7 Early clinical studies demonstrated that an LT4:LT3 ratio of 4:1 produced a similar clinical response compared with desiccated thyroid extract 8 and returned patients to euthyroid status as determined by clinical markers, including normalised cholesterol and protein-bound iodine levels. 10 In 1970, it was demonstrated that the serum T3 found in the blood of patients receiving LT4 monotherapy was derived from peripheral conversion of the administered LT4. 11 This finding provided a mechanism to explain the observation that circulating T3 levels were physiologic in patients treated with LT4 monotherapy, 12 implying that exogenous LT3 was not required for the treatment of hypothyroidism. A prospective, well-controlled study by Jonklaas and colleagues compared circulating T3 and T4 levels in 50 patients before and after they underwent near-total or total thyroidectomy. 13 LT4 monotherapy resulted in normalised T3 levels in patients, further suggesting that T3 treatment is not required to achieve the usual endogenous levels of T3 13 although not all studies confirmed these findings (see below). Research in rats has indicated that, in certain tissue types, increased T4 levels inhibit endogenous conversion of T4 to T3; however, it is acknowledged that this effect is likely to be relatively modest in humans because of interspecies differences in peripheral conversion. 14 Despite this,
Review criteria
• There is long-standing debate about whether addition of levotriiodothyronine (LT3) to levothyroxine (LT4) will ameliorate persistent symptoms of hypothyroidism. To explore the evidence for and against LT4/LT3 combination therapy, recent literature was searched using the terms "hypothyroid" or "hypothyroidism" and "triiodothyronine combination" or "T3 combination." In all, 72 relevant non-review articles published in English were found;
17 were included and supplemented with articles already known to the authors.
Message for the clinic
• Current clinical evidence is insufficient to support LT4/LT3
combination therapy in patients with hypothyroidism. there remains a persistent concept that addition of LT3 has a role in the treatment of hypothyroidism, that is, to improve persistent symptoms. 15 Others point to findings that approximately one-fifth of thyroidectomised patients treated with LT4 in a large retrospective study did not have free T3 or free T4 in the reference range although TSH levels were normal. 16 They argue that conversion of LT4 to T3 is not adequate in some patients, who may benefit from addition of LT3 to ameliorate lingering symptoms. However, the study itself did not evaluate such symptoms, so it is not known whether values of free T3 and free T4 outside the reference range were associated with or responsible for continuing complaints in euthyroid patients receiving LT4. 16 Across clinical studies, patients
with hypothyroidism who attained normal TSH levels with LT4 treatment had free LT3 levels that were, in general, statistically lower than controls (although often still in the expected laboratory range) and free T4 levels that were generally within normal limits although mean values were higher than in control subjects.
However, there were many variations in the dosing, TSH results and timing of the blood draw in relation to ingestion of LT4 among these studies, which likely affected the observed levels of T3, T4
and T4/T3 that were reported.
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| Hypotheses supporting LT3 replacement: Genetic evidence

What is the proposed biological rationale for considering LT3 in combination with LT4?
In the periphery, T4 is converted to T3 by deiodinases. In initial studies, the D2-ORFa-Gly3Asp polymorphism, but not the D2-Thr92Ala polymorphism, was correlated with lower levels of some circulating thyroid hormones, including plasma T4 and free T4
but not T3 or free T3. 27, 28 In an early clinical trial (N = 141), however, no relationship was seen between either D2 polymorphism and neurocognitive outcomes, well-being, or treatment preference in patients randomised to double-blind treatment with LT4 alone or LT4/LT3 combination therapy. 29 A larger post hoc analysis 30 examined patients (N = 552) receiving stable LT4 monotherapy who either remained on monotherapy or were switched to LT4/LT3 combination therapy for 12 months. 31 Despite a large placebo effect in both treatment groups, a small but statistically significant between-treatment difference of 2.3 points on the General Health Questionnaire (GHQ)-12 was seen at 3 months that favoured LT4/LT3 therapy versus LT4 monotherapy in patients with the D2-Thr92Ala polymorphism; however, the difference of 1.4 points at 12 months was not significant. No differences were observed in thyroid hormone levels with LT4/LT3 treatment, however, and, most importantly, the study was underpowered to detect gene-treatment interactions because of the low frequency of this polymorphism in the population (16%).
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Most recently, the effects of the D2-Thr92Ala polymorphism were investigated in a cross-sectional study of 12 625 participants from the LifeLines cohort, including 364 (88% female) patients who received LT4 treatment. 32 In both populations, no correlations were noted between the polymorphism and thyroid parameters, health-related quality of life (QoL), cognitive functioning, the presence of metabolic syndrome, or the use of blood pressure or cholesterol-lowering drugs. 32 However, the women receiving LT4 (only 52% of whom had a TSH level in the expected range) had impaired QoL, compared with age-and body mass index (BMI)-matched healthy controls, and authors speculated that this impairment may have been related to comorbid conditions. 32 Given that these recent results contradict earlier research, further studies are needed to fully understand the implications of D2 polymorphisms in the treatment of overt hypothyroidism. 33 Patients who reported changes in ≥7 symptoms from a panel of typical traditional hypothyroid symptoms in the past year were significantly more likely to be hypothyroid. 33 However, it should be noted that many patients newly diagnosed with overt hypothyroidism complain of no or few current or changed symptoms. 33 The same investigators demonstrated that the percentage of euthyroid and hypothyroid patients presenting with a series of individual symptoms was quite similar, further illuminating the difficulty that clinicians may have in detecting overt hypothyroidism by symptoms alone when confronted with an array of nonspecific complaints. 34 Additionally, more than 15% of euthyroid individuals complain of more than four typical hypothyroid symptoms, 34 • There were no significant differences overall in mood or cognitive function with LT4/LT3 vs LT4 alone • No significant between-group differences were seen in measures of fatigue, depression, working memory
| Associations between thyroid hormone levels and patient-reported symptoms
• No significant between-group differences were seen regarding hypothyroid symptoms
• Among the 27 who completed the study, 7 preferred LT4, 8 had no preference and 12 preferred LT4/LT3
Saravanan et al, • No between-treatment differences in TSH were noted at BL or 6 mo
• Total and LDL cholesterol levels were significantly lower with LT4/LT3 vs LT4
• No between-group differences in heart rates were • Free T4 levels were significantly lower and resting heart rate was slightly higher with LT4/LT3 vs LT4 monotherapy
• Other outcomes (QoL, lipids, BMI) were similar AE, adverse event; BL, baseline; BMI, body mass index; GHQ, General Health Questionnaire; HADS, Hospital Anxiety and Depression Scale; LDL, low-density lipoprotein; QoL, quality of life; LT4, levothyroxine; LT3, levotriiodothyronine; TSH, thyroid-stimulating hormone.
T A B L E 1 (Continued)
absence of sensitive thyroid function testing of TSH, with or without testing of free T4. for the appropriate treatment of thyroid carcinoma. These individuals had been receiving LT4 suppression at a stable dose for at least the previous 10 weeks and had median TSH levels of 0.042 mIU/L (below the expected range) and median T3 levels of 1.93 nmol/L (well within the expected range). 40 Overall, QoL was lower in these patients than in a reference population. No associations were noted between thyroid function test results (including TSH, free T4, total T4 and total T3) and measures of QoL or fatigue. 40 A determinant of QoL measures in these patients was the total number of medications with which they were being treated, but not whether they had been told they were cured of their cancer, had a higher BMI, or had developed hypoparathyroidism as a result of the surgery. QoL was also related to the time since their initial diagnosis of thyroid cancer, with increase in positive QoL associated with increasing time since the initial diagnosis. These findings suggested that the nonspecific complaints of fatigue or impaired well-being in patients with hypothyroidism are not predictably due to a deficiency of circulating T3 and would not be expected to improve by increasing either the LT4 dose or adding LT3 therapy.
A recently published study of NHANES data investigated whether 469 individuals who were receiving LT4 at doses sufficient to produce normal levels of TSH are similar to matched healthy control subjects in terms of thyroid function, thyroid-hormone-related markers and other clinical factors. 41 Some differences in hormone levels and clinical parameters were identified in patients compared with healthy controls, including lower serum free and total T3, relatively higher serum free and total T4, and thus higher T4:T3 ratios. The values of free T3 and free T4 were no different in patients with higher normal TSH ( ≥ 1.75 mIU/L) compared with those with lower normal TSH ( < 1.75 mIU/L). Overall, patients treated with LT4 were significantly more likely to be concomitantly treated with beta-blockers, statins and antidepressants than their matched controls, yet they had similar QoL and neuropsychiatric measures. In multivariate regression, the T4:T3 ratio was significantly associated with age and calorie consumption in patients treated with LT4 and with age and sex in matched controls. 41 The authors concluded that LT4 treatment in patients with hypothyroidism, even when TSH is normalised, does not produce a euthyroid state because (for unknown reasons) BMI is higher although calorie intake and physical activity are lower than in healthy subjects. 41 
| Clinical studies of LT4/LT3 combination therapy versus LT4 monotherapy
The patient in the case presentation has asked about treatment with a combination of LT4 and LT3 instead of her current LT4 monotherapy.
What is the clinical evidence that this therapeutic adjustment would im-
prove her persistent symptoms?
| Individual studies
Studies comparing QoL, mood and cognitive outcomes and patients' preference for treatment with LT4/LT3 combination therapy versus LT4 monotherapy are described in Table 1 . 22, 31, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] Among these 17 studies, 1 older study using very high LT4 and LT4/LT3 doses found that LT4 monotherapy had a more favourable adverse event profile
and was preferred by patients versus LT4/LT3 combination therapy.
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This study should likely be viewed from a historical perspective only because the conditions of treatment are dissimilar to the more modern studies listed below. 54 Of the remaining 16 studies, 4 (comprising five publications) found that LT4/LT3 combination therapy versus LT4 monotherapy produced improvements in QoL, mood and/or cognition. [43] [44] [45] 50, 55 In two studies without obvious objective differentiation, the authors nonetheless noted a subjective preference for LT4/ LT3 combination therapy over LT4 monotherapy. 22, 42 The results of 10 studies, however, were neutral, finding no consistent advantage for monotherapy or combination treatment. 31, [46] [47] [48] [49] [51] [52] [53] 56, 57 Thus, the comparisons of LT4/LT3 combination therapy versus LT4 monotherapy produced mixed and equivocal results. It should be noted that there were large placebo effects in two of these studies: one that found an advantage with LT4/LT3 combination treatment and one in which results did not favour either treatment. 31, 50 This suggests that patients who undergo adjustment of thyroid hormones can experience changes in mood that may not be attributable to active treatment.
| Integrated analyses
Given the ambiguous and conflicting results of individual studies, monotherapy. 58 A meta-analysis of 11 randomised trials (N = 1216)
found no differences in bodily pain, depression, anxiety, fatigue, cognitive function or QoL outcomes in patients treated with LT4/ LT3 combination therapy versus LT4 monotherapy. 59 In 2007, a meta-analysis of nine controlled studies (N = 1141) also found that there was no significant difference between LT4/LT3 and LT4 therapy in measures of mood although the authors noted that combined treatment was the preferred treatment in the studies that measured patient preference (no preference, 23%; preference for LT4, 32%;
preference for LT4/LT3, 46%). 60 The fourth integrated analysis, a meta-analysis of 10 randomised double-blind trials (N = 1153), found nothing but sporadic improvements associated with LT4/LT3 versus LT4 therapy in mood, cognitive function, QoL outcomes or adverse effects. 61 By this analysis, no difference was noted in patient preference between treatment regimens. alone compared with T3 alone. 64 The use of an alternative LT3 formulation 65 or LT3 dosing 3 times a day may be required to fully evaluate the effectiveness of combination treatment.
36,62,66
| Other considerations for LT4/LT3 combination therapy
As already described, individual results from most controlled studies and results from integrated analyses indicated that there were no significant differences in outcomes with LT4/LT3 or LT4 treatment. However, the reports had aspects that limit the extent to which their findings can be extrapolated. The results were derived from relatively short-term trials, with the longest study extending 1 year. 31 A large, long-term observational study with a maximum 17-year followup evaluated morbidity and mortality in patients treated with LT3
(n = 400; 327 patients received the LT3 with LT4, and 73 patients received LT3 alone) or LT4 alone (n = 33 955). 67 No statistically significant between-treatment differences were observed in the incidences of death, cardiovascular disease, atrial fibrillation, diabetes or fracture outcomes. 67 The only difference that reached statistical significance was an increase in the new use of antipsychotic drugs, an effect that was associated with the use of LT3 (adjusted hazard ratio, 2.26 [95% CI, 1.64-3.11]; P < .01). 67 These data suggest that long-term treatment with LT3 is generally safe although the preponderance of longterm experience in the treatment of hypothyroidism involves LT4 monotherapy.
A common theme of analyses of patients with hypothyroidism is that they have poorer overall health relative to matched controls.
Although statistical methods may be used to adjust for these confounding factors in a large population, this is impossible for the in- At the very least, consideration of these alternative explanations for the nonspecific symptoms occurring in patients who otherwise appear hypothyroid seems inherently appropriate. Continued attribution of these symptoms to a hypothyroid state in the face of normal TSH may result not only in the misdiagnosis of some potentially serious conditions (Table 2 ), but also serious exacerbation of symptoms or threat to life if, for example, adrenal insufficiency goes unrecognised.
Adjustment of the approach to thyroid hormone replacement by adding LT3 for nonspecific symptoms seems to lack a substantial predictive prospect of success. As the physician seeks the correct underlying cause of the symptom, the patient may require assurance that hypothyroidism is unlikely to be the problem.
| Guideline recommendations
Guidelines for the treatment of patients with hypothyroidism consistently recommend LT4 monotherapy as the treatment of choice, recommend against the routine use of LT4/LT3 combination treatment, and recommend against the use of desiccated thyroid extract.
Recommendations from recent clinical practice guidelines on treatment goals, LT4 monotherapy, LT4/LT3 combination therapy, use of desiccated thyroid extract and the role of genotyping in the treatment of hypothyroidism are presented in Table 3 . It is estimated that 5%-10% of patients with hypothyroidism treated with LT4 with normal TSH levels continue to experience nonspecific symptoms which may be attributed to hypothyroidism. 73 Current clinical evidence, however, is not sufficiently strong 
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